Caleb Skipper is an Infectious Disease physician affiliated with University of Minnesota. OpenAlex indexes 70 publications with 3,387 citations (h-index 22).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2450 Riverside Ave
Minneapolis, MN 554541450
Telephone
612-672-6000Provider last certified this registry record 22 Mar 2024.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Insmed, Inc.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2022)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Cephalosporin Antibacterial100%Ceftriaxone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2023–2025 per NIH RePORTER. The latest:
- Improving diagnosis of High ICP in Cryptococcal meningitis (ICP-CRYPTO)
University of Minnesota
FY2025$404,060R21AI195264 - Impact of longitudinal CMV viremia on opportunistic neuroinfections in advanced HIV disease
University of Minnesota
FY2025$239,490K23NS137968 - Impact of longitudinal CMV viremia on opportunistic neuroinfections in advanced HIV disease
University of Minnesota
FY2024$239,490K23NS137968
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Impact of cerebrospinal fluid leukocyte infiltration and activated neuroimmune mediators on survival with HIV-associated cryptococcal meningitis
PLoS neglected tropical diseases
2025 - Valganciclovir for cytomegalovirus viraemia in advanced HIV disease: a phase 2b randomized placebo-controlled trial of valganciclovir for cytomegalovirus viraemia in adults and adolescents with advanced HIV disease
Philosophical Transactions of the Royal Society B Biological Sciences
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Bruce Blazar, MD
University of Minnesota
Jay Cohn, MD
University of Minnesota
Julia Steinberger, MD
University of Minnesota
Charles Herzog, MD
University of Minnesota
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”